Visudyne (verteporfin): Information on the continuing supply limitation until end of 2023

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Visudyne
Active substance
verteporfin
Therapeutic area (MeSH)
  • Myopia, Degenerative
  • Macular Degeneration
Procedure number
EMEA/H/C/000305
Regulatory outcome
Maintenance
DHPC type
Medicine shortage
Human ATC code
S01LA01
Dissemination date
12/08/2022

How useful was this page?

Add your rating